136 related articles for article (PubMed ID: 23489263)
1. Glutathione-S-transferase T1 genotyping and phenotyping in psoriasis patients receiving treatment with oral fumaric acid esters.
Gambichler T; Kreuter A; Susok L; Skrygan M; Rotterdam S; Höxtermann S; Müller M; Tigges C; Altmeyer P; Lahner N
J Eur Acad Dermatol Venereol; 2014 May; 28(5):574-80. PubMed ID: 23489263
[TBL] [Abstract][Full Text] [Related]
2. Val/Val glutathione-S-transferase P1 polymorphism predicts nonresponders in psoriasis patients treated with fumaric acid esters.
Gambichler T; Susok L; Zankl J; Skrygan M
Pharmacogenet Genomics; 2016 May; 26(5):248-53. PubMed ID: 26967570
[TBL] [Abstract][Full Text] [Related]
3. Regulated genes in psoriatic skin during treatment with fumaric acid esters.
Onderdijk AJ; Balak DM; Baerveldt EM; Florencia EF; Kant M; Laman JD; van IJcken WF; Racz E; de Ridder D; Thio HB; Prens EP
Br J Dermatol; 2014 Oct; 171(4):732-41. PubMed ID: 24852654
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
5. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.
Inzinger M; Weger W; Heschl B; Salmhofer W; Quehenberger F; Wolf P
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):861-6. PubMed ID: 22672248
[TBL] [Abstract][Full Text] [Related]
7. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Balasubramaniam P; Stevenson O; Berth-Jones J
Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
[TBL] [Abstract][Full Text] [Related]
8. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study.
Schmieder A; Poppe M; Hametner C; Meyer-Schraml H; Schaarschmidt ML; Findeisen P; Benoit S; Bauer B; Schmid S; Goebeler M; Goerdt S; Ludwig-Peitsch WK
Arch Dermatol Res; 2015 Jul; 307(5):413-24. PubMed ID: 25648959
[TBL] [Abstract][Full Text] [Related]
9. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
Höxtermann S; Nüchel C; Altmeyer P
Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412
[TBL] [Abstract][Full Text] [Related]
10. Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?
Philipp S; Kokolakis G; Hund M; Witte E; Witte K; Kunz S; Roewert HJ; Sterry W; Sabat R
Eur J Dermatol; 2013; 23(3):339-43. PubMed ID: 23774790
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands.
Balak DM; Oostveen AM; Bousema MT; Venema AW; Arnold WP; Seyger MM; Thio HB
Br J Dermatol; 2013 Jun; 168(6):1343-7. PubMed ID: 23738641
[TBL] [Abstract][Full Text] [Related]
12. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
[TBL] [Abstract][Full Text] [Related]
13. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
[TBL] [Abstract][Full Text] [Related]
14. Disseminated granuloma annulare--treatment with fumaric acid esters.
Eberlein-König B; Mempel M; Stahlecker J; Forer I; Ring J; Abeck D
Dermatology; 2005; 210(3):223-6. PubMed ID: 15785051
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
Mrowietz U; Christophers E; Altmeyer P
Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS).
Thaçi D; Weisenseel P; Philipp S; Rosenbach T; Rotterdam S; Augustin M; Neureither M; Reich K
J Dtsch Dermatol Ges; 2013 May; 11(5):429-35. PubMed ID: 23433431
[TBL] [Abstract][Full Text] [Related]
17. Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial.
Balak DM; Fallah-Arani S; Venema CM; Neumann HA; Thio HB
Br J Dermatol; 2015 Mar; 172(3):754-9. PubMed ID: 25041291
[TBL] [Abstract][Full Text] [Related]
18. Fumaric acid and its derivatives in the treatment of psoriasis vulgaris: our experience in forty-one patients.
Kokelj F; Plozzer C; Avian A; Trevisan G
Acta Dermatovenerol Croat; 2009; 17(3):170-5. PubMed ID: 19818215
[TBL] [Abstract][Full Text] [Related]
19. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.
Harries MJ; Chalmers RJ; Griffiths CE
Br J Dermatol; 2005 Sep; 153(3):549-51. PubMed ID: 16120141
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
